Literature DB >> 8616707

The cost of treating Gaucher disease.

E Beutler1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8616707     DOI： 10.1038/nm0596-523

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  4 in total

Review 1.  Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders.

Authors:  Carla E M Hollak; Johannes M F G Aerts; Ségolène Aymé; Jeremy Manuel
Journal:  Orphanet J Rare Dis       Date:  2011-04-16       Impact factor: 4.123

2.  Ethics, policy, and rare genetic disorders: the case of Gaucher disease in Israel.

Authors:  Michael L Gross
Journal:  Theor Med Bioeth       Date:  2002

3.  Growing older: the adult metabolic clinic.

Authors:  P J Lee
Journal:  J Inherit Metab Dis       Date:  2002-05       Impact factor: 4.982

4.  Registries for orphan drugs: generating evidence or marketing tools?

Authors:  Carla E M Hollak; Sandra Sirrs; Sibren van den Berg; Vincent van der Wel; Mirjam Langeveld; Hanka Dekker; Robin Lachmann; Saco J de Visser
Journal:  Orphanet J Rare Dis       Date:  2020-09-03       Impact factor: 4.123
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.